+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 34 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the efficacy and safety of elecoglipron for weight management in adults living with obesity or overweight. This Phase III global study includes two independent, randomized, double-blind, placebo-controlled pivotal studies. Study 1 involves adults without type 2 diabetes mellitus T2DM, while Study 2 includes adults with T2DM. Participants have obesity or overweight with at least one weight-related comorbidity such as hypertension, prediabetes, dyslipidemia, cardiovascular disease, or obstructive sleep apnea. Participants will be randomly assigned to receive one of two doses of elecoglipron or a placebo once daily as oral tablets. The treatment lasts 72 weeks, and the study is conducted in multiple centers worldwide. The primary measure is the percentage change in body weight from baseline at 72 weeks. Secondary measures include absolute weight loss, achievement of specific weight loss percentages, waist circumference reduction, glycemic control, and systolic blood pressure reduction. Throughout the study, participants will undergo regular assessments including body weight and waist measurements, laboratory tests related to glycemic control, and blood pressure monitoring. Researchers will also track the achievement of normoglycemia and glycemic control in participants with elevated HbA1c levels. Safety and efficacy data will be collected until the study completion in 2029, with participants monitored closely during the 72-week treatment period.

Age: 18Years +All GendersPhase 3
325 locations
S

Actively Recruiting

Researchers are evaluating the effect of a triple therapy inhaler containing budesonide, glycopyrronium, and formoterol fumarate BGF MDI 32014.49.6 g compared to a dual therapy inhaler with glycopyrronium and formoterol fumarate GFF MDI 14.49.6 g on heart and lung outcomes in adults with chronic obstructive pulmonary disease COPD who have increased cardiopulmonary risk. This is a Phase III randomized, double-blind, parallel group, multi-center study designed to assess these treatments over an extended period. Participants will be randomly assigned to receive either the triple therapy BGF MDI or the dual therapy GFF MDI, each administered twice daily. The study aims to track the time to first severe cardiac or COPD event over up to three years. Both treatments involve pressurized inhalation suspensions delivered by metered-dose inhalers, and the study includes ongoing monitoring for up to three years during which various cardiopulmonary events and exacerbations will be recorded. During the study, participants will attend visits where their inhaler technique, lung function, blood markers such as eosinophil counts, and COPD assessment test scores will be evaluated. Researchers will measure outcomes including time to severe COPD exacerbations, cardiac events, cardiopulmonary death, and hospitalizations related to heart issues. Safety and efficacy will be closely monitored throughout the study duration, which may last up to three years, with regular follow-up assessments conducted in person or virtually as needed.

Age: 40Years - 80YearsAll GendersPhase 3
922 locations
E

Actively Recruiting

Researchers are evaluating the efficacy of Galvokimig compared to a placebo in adults with non-cystic fibrosis bronchiectasis NCFB. The study aims to determine how Galvokimig affects the time to the first moderate or severe lung infection episode, known as a pulmonary exacerbation. The trial is a randomized, double-blind, placebo-controlled Phase 2 study involving adult participants aged 18 to 80 years with confirmed NCFB. Participants are randomly assigned to receive one of three doses of Galvokimig or a matching placebo. Treatment lasts between 24 and 52 weeks, with dosing schedules and details managed under careful medical supervision. The study includes a comparison of different dose levels of Galvokimig to evaluate safety and effectiveness in preventing lung exacerbations. During the study, participants will undergo regular assessments including lung function tests measured by post-bronchodilator forced expiratory volume in 1 second FEV1, quality of life questionnaires related to respiratory symptoms, and monitoring for any adverse events. Researchers will track lung infections and overall respiratory health up to 52 weeks, with safety follow-up extending to 60 weeks. Participants health will be closely monitored throughout the trial to collect data on the treatments impact and safety.

Age: 18Years - 80YearsAll GendersPhase 2
6 locations
E

Actively Recruiting

Researchers are evaluating the drug Galvokimig compared to a placebo to see how it affects the time until the first acute worsening exacerbation of chronic obstructive pulmonary disease COPD in people with moderate-to-severe COPD who also have chronic bronchitis. This Phase 2 study focuses on participants aged 40 to 80 with a history of COPD exacerbations and chronic bronchitis symptoms. Participants are randomly assigned to receive one of two predefined doses of Galvokimig or a matching placebo. The study treatment is given as a solution for injection over a period ranging from 24 to 52 weeks. The purpose is to assess the drugs effect on reducing the frequency and timing of COPD exacerbations during this treatment phase. During the study, participants will be monitored regularly to measure lung function, quality of life related to respiratory health, and the number and severity of COPD exacerbations. Safety is closely followed by tracking adverse events up to 60 weeks. The main outcome is the time until the first moderate or severe COPD exacerbation, with additional assessments including lung function tests and patient questionnaires. Total study participation may last up to about 60 weeks.

Age: 40Years - 80YearsAll GendersPhase 2
23 locations
E

Actively Recruiting

Researchers are evaluating different dose levels of Brenipatide in adults with moderate-to-severe Chronic Obstructive Pulmonary Disease COPD. The study aims to assess the safety and effectiveness of Brenipatide compared to a placebo over approximately one year. This Phase 2 trial focuses on how the drug works alongside standard care in people with COPD who have a history of smoking and recent exacerbations. Participants are randomly assigned to receive either a low dose or high dose of Brenipatide or a placebo, all given by subcutaneous injection. All groups continue their standard care therapy, which may include long-acting bronchodilators or inhaled corticosteroids. The treatment period lasts 52 weeks, during which participants receive the study drug or placebo alongside their regular medications. Throughout the study, participants will have lung function tests measuring forced expiratory volume FEV1 before bronchodilator use at baseline and at several weeks up to week 52. Researchers will also monitor COPD exacerbation rates and quality of life using specific questionnaires. Safety and treatment effects are assessed regularly to understand how Brenipatide performs in managing COPD symptoms and lung function over one year.

Age: 40Years - 75YearsAll GendersPhase 2
127 locations
E

Actively Recruiting

Researchers are evaluating depemokimab as an add-on treatment for adolescents and adults with Type 2 asthma who are at risk of flare-ups. The study compares depemokimab plus standard care with a placebo plus standard care to assess the effect on asthma exacerbations and other health outcomes. This Phase 3b4 trial is designed to understand how early intervention with depemokimab impacts lung function, asthma control, and safety over up to 156 weeks. Participants are randomly assigned to receive either depemokimab or a placebo, both alongside their usual asthma treatment. The study uses a double-blind design, meaning neither participants nor researchers know which treatment is given. Treatment and assessments occur over about three years with regular monitoring of lung function and asthma symptoms. The trial includes a detailed evaluation of quality of life and asthma control scores at baseline and after two years. Participants will be involved in regular visits for lung function tests and questionnaires about their asthma control and quality of life. Researchers will track the annual rate of significant asthma exacerbations, improvements in clinical remission, and changes in lung function. Safety and adherence to treatment are also monitored throughout the study. The entire participation can last up to 156 weeks, with ongoing assessments to evaluate how the study drug affects participants asthma.

Age: 12Years +All GendersPhase 3
17 locations
S

Actively Recruiting

Researchers are studying WIN378, a long-acting medicine, in adults with moderate to severe chronic obstructive pulmonary disease COPD. WIN378 targets a protein called TSLP that causes lung inflammation and may influence COPD symptoms and control. This Phase 2a trial aims to find the right dose by assessing safety, how the body processes the medicine, and its effects on markers of inflammation, lung function, and disease control. Participants will receive subcutaneous injections of WIN378 at different doses or a placebo over a 24-week treatment period while continuing their usual COPD therapies. The study is randomized, double-blind, and placebo-controlled, ensuring a thorough comparison of effects. The treatment phase lasts 24 weeks, followed by monitoring up to 36 weeks for safety and drug concentration in the blood. During the study, participants will undergo lung function tests, blood tests, and exhaled breath analyses to assess inflammation and COPD control. Researchers will monitor vital signs, laboratory parameters, and any adverse events throughout the 36-week period. The trial also tracks the presence of antibodies against WIN378. Participants are involved in regular evaluations to help understand how the medicine works and its safety profile.

Age: 40Years - 80YearsAll GendersPhase 2
32 locations
A

Actively Recruiting

Researchers are evaluating the effectiveness and safety of a new drug called GSK3862995B in adults with bronchiectasis, a chronic lung disease. This Phase 2 study also examines how the body processes the drug and checks for any immune reactions. Participants will be randomly assigned to receive one of two doses of GSK3862995B or a placebo to compare their effects on bronchiectasis. Participants will receive either Dose Level 1 or Dose Level 2 of GSK3862995B, or a matching placebo. The study uses a double-blind, randomized design, meaning neither participants nor researchers know who gets which treatment. The treatment period lasts up to 48 weeks, during which participants receive repeated doses. The study also includes assessments up to 72 weeks to monitor safety and immune responses. During the trial, participants will undergo evaluations including lung function tests, quality-of-life questionnaires, and monitoring of respiratory symptoms. Researchers will track the number of lung exacerbations, serious adverse events, laboratory tests, vital signs, and electrocardiograms to assess safety and effectiveness. Participants will be involved in regular visits and assessments throughout the treatment and follow-up periods, lasting up to about 72 weeks in total.

Age: 18Years - 85YearsAll GendersPhase 2
134 locations
E

Actively Recruiting

Researchers are evaluating the effects of once daily treatment with Treprostinil Palmitil Inhalation Powder TPIP compared with a placebo in adults with progressive pulmonary fibrosis PPF. This Phase 3 randomized, double-blind, placebo-controlled study aims to assess lung function and safety over a long period, focusing on patients with interstitial lung disease who have shown disease progression despite standard treatments. Participants will be randomly assigned to receive either TPIP or a matching placebo once daily for up to 104 weeks. The starting dose of TPIP is 80 micrograms and may be increased to the maximum tolerated dose of 1280 micrograms. Both treatments are inhaled using a capsule-based dry powder inhaler device. The study uses a parallel group design and includes a placebo comparator. During the study, participants will undergo regular assessments including lung function tests such as forced vital capacity FVC and diffusing capacity for carbon monoxide DLCO. Researchers will monitor clinical worsening events, acute exacerbations, symptom scores, plasma drug concentrations, and any adverse events for up to two years. The primary outcome is the change in absolute FVC from baseline to week 52. Participants will be closely monitored throughout the treatment period to evaluate efficacy and safety.

Age: 18Years - 85YearsAll GendersPhase 3
1 location
E

Actively Recruiting

Researchers are evaluating AZD0292, a bispecific IgG1k monoclonal antibody, for preventing exacerbations in patients aged 12 years and older with bronchiectasis who are chronically colonized with Pseudomonas aeruginosa PsA. This Phase IIb study compares two intravenous dosage regimens of AZD0292 to placebo, including participants with non-cystic fibrosis bronchiectasis NCFBE and an exploratory group with cystic fibrosis CF bronchiectasis. Participants will receive either a high dose or low dose of AZD0292 or placebo via IV infusion starting on Day 1, with further doses given according to the study schedule. The study uses a randomized, double-blind, placebo-controlled, parallel design to assess the drugs efficacy, safety, and pharmacokinetics. The primary focus is on PsA-colonized bronchiectasis patients who have frequent pulmonary exacerbations, with treatment continuing for a variable follow-up period. During the study, participants will be monitored regularly for exacerbation rates, lung function, quality of life measures, and adverse events. Assessments include sputum cultures, pulmonary function tests, serum pharmacokinetic sampling, and questionnaires like the QOL-B-RSS and SGRQ. Safety monitoring extends up to 24 weeks after the last dose, and the study duration varies from at least 28 weeks to a maximum of 52 weeks of follow-up.

Age: 12Years +All GendersPhase 2
186 locations

1-10 of 34

1